# EDGAR Filing Document

**Accession Number:** 0001501756
**File Stem:** 0001628280-23-009895
**Filing Date:** 2023-3
**Character Count:** 19787
**Document Hash:** ac44d09af25fefa8e8c74ade47c2acea
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-23-009895.hdr.sgml**: 20230330

**ACCESSION NUMBER**: 0001628280-23-009895

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20230330

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230330

**DATE AS OF CHANGE**: 20230330

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Adverum Biotechnologies, Inc.
- **CENTRAL INDEX KEY:** 0001501756
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 205258327
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36579
- **FILM NUMBER:** 23780762

**BUSINESS ADDRESS:**
- **STREET 1:** 100 CARDINAL WAY
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063
- **BUSINESS PHONE:** (650) 649-1004

**MAIL ADDRESS:**
- **STREET 1:** 100 CARDINAL WAY
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Avalanche Biotechnologies, Inc.
- **DATE OF NAME CHANGE:** 20100921

?xml version="1.0" ? advm-20230330

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington**, **D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**March 30, 2023**

**Date of Report (Date of earliest event reported)**

**Adverum Biotechnologies, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36579** | **20-5258327** |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission<br>File Number)** | **(I.R.S. Employer<br>Identification No.)** |

---

**100 Cardinal Way**

**Redwood City, CA 94063**

**(Address of principal executive offices, including zip code)**

**(650) 656-9323**

**(Registrant's telephone number, including area code)**

**N/A**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| **Common Stock** | **ADVM** | **Nasdaq Global Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition.**

On March 30, 2023, Adverum Biotechnologies, Inc. issued a press release announcing its financial results for the full year and quarter ended December 31, 2022, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in this report, including the exhibit hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Adverum Biotechnologies, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[Press Release dated](exhibit991_33023pressrelea.htm)[March](exhibit991_33023pressrelea.htm)[3](exhibit991_33023pressrelea.htm)[0, 202](exhibit991_33023pressrelea.htm)[3](exhibit991_33023pressrelea.htm)[, announcing Adverum Biotechnologies, Inc. financial results for the quarter ended](exhibit991_33023pressrelea.htm)[Dec](exhibit991_33023pressrelea.htm)[ember](exhibit991_33023pressrelea.htm)[3](exhibit991_33023pressrelea.htm)[1](exhibit991_33023pressrelea.htm)[, 2022, and providing a corporate update.](exhibit991_33023pressrelea.htm)</u> |
| 104 | The cover page of this report has been formatted in Inline XBRL. |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **Adverum Biotechnologies, Inc.** | **Adverum Biotechnologies, Inc.** |
| Date: March 30, 2023 | By: | /s/ Laurent Fischer |
|  |  | Laurent Fischer, M.D. <br>President and Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![logo.jpg](logo.jpg)

**Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update**

*-Full enrollment of the LUNA trial anticipated in the second half of 2023-*

*-LUNA 14-week data including initial aflibercept levels anticipated in the third quarter 2023-*

*-LUNA preliminary efficacy and safety data anticipated in the fourth quarter of 2023-*

-Cash runway into 2025 -

**REDWOOD CITY, Calif.**, Mar. 30, 2023 -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on its ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) for the treatment of wet age-related macular degeneration (wet AMD).

"Our Phase 2 LUNA trial continues to enroll, and we are pleased with the enthusiasm from investigators and progress in the number of participants screened for the trial to date," stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies. "We expect to complete the LUNA study enrollment in the second half of 2023 and are engaging with European health authorities in anticipation of enrolling LUNA subjects in Europe, in addition to the U.S. clinical trial sites. We also plan to provide interim datasets for a percentage of participants in the LUNA study at 14 weeks, including aflibercept protein levels, in the third quarter of 2023, as well as preliminary efficacy and safety data in the fourth quarter of 2023."

"The long-term efficacy and safety profile after a single intravitreal (IVT) injection of Ixo-vec, beyond two years in the 2x10^11 vg/eye dose in OPTIC extension subjects is remarkable. I am excited to have enrolled my first subject in the Phase 2 LUNA trial. The 2x10^11 and 6x10^10 doses of Ixo-vec are being evaluated with enhanced corticosteroid prophylaxis so the subjects can benefit from the efficacy of a single IVT injection of Ixo-vec while minimizing the risk of inflammation," said Arshad M. Khanani M.D., M.A., managing partner and director of clinical research, Sierra Eye Associates, member of Adverum's Scientific Advisory Board, and lead principal investigator in the Phase 2 LUNA trial.

**Recent Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Phase 2 LUNA trial evaluating Ixo-vec in subjects with wet AMD continues to enroll. Up to 72 participants will be randomized equally across two doses, the 2x10^11 (2E11) vg/eye dose and a new, lower 6x10^10 (6E10) vg/eye dose. Four prophylactic corticosteroid regimens will be studied that cover the period of peak immunogenicity observed in non-clinical studies and in the Phase 1 OPTIC study. Specific regimens being evaluated include 22 weeks of a tapered regimen of topical difluprednate (Durezol<sup>®</sup>), a single administration of IVT dexamethasone (Ozurdex<sup>®</sup>), and a combination

------

of either topical Durezol<sup>®</sup> or IVT Ozurdex<sup>®</sup> with up to 10 weeks of a tapered regimen of oral prednisone, with the aim of establishing a prophylactic regimen with minimal need for inflammation management post prophylaxis.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In November 2022, Adverum presented end-of-study results from its Phase 1 OPTIC trial of Ixo-vec across the 6x10^11 (6E11) and 2E11 doses in wet AMD at The Retina Society Annual Meeting. New data presented included final two-year efficacy and safety analyses, including reduction in annualized anti-VEGF injections, clinically relevant and stable aflibercept protein levels and maintenance to improvement of mean best-corrected visual acuity (BCVA) and mean central subfield thickness (CST).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Ixo-vec was generally well tolerated with dose-dependent inflammation that was responsive to topical corticosteroids.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ All participants dosed at 2E11 were inflammation-free and did not require corticosteroids to treat inflammation at the end of the study.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ OPTIC trial participants had an 80% - 98% reduction in annualized anti-VEGF injections and continuous therapeutic aflibercept protein levels, demonstrated through three years in extension study participants.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ 80% and 53% of participants were supplemental injection-free over two years for the 6E11 and 2E11 dose groups, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Mean BVCA and mean CST were maintained to improved through at least two years at both doses.

**Anticipated Phase 2 LUNA Trial 2023 Milestones**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **2H 2023** – Anticipate full enrollment of the Phase 2 LUNA trial

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Q3 2023** – Anticipate LUNA 14-week data including aflibercept levels for a percentage of cohort

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Q4 2023** – Anticipate LUNA preliminary efficacy and safety data

**Financial Results for the Three Months Ended December 31, 2022** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Cash, cash equivalents and short-term investments** were $185.6 million as of December 31, 2022, compared to $203.3 million as of September 30, 2022, and $305.2 million as of December 31, 2021. Adverum expects cash, cash equivalents and short-term investments to fund operations into 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Research and development expenses** were $22.2 million for the three months ended December 31, 2022, compared to $22.5 million for the same period in 2021. Research and development expenses decreased slightly due to lower consultant, outside R&D services, compensation expenses following restructuring, and facilities related expenses, partially offset by higher clinical trial related expense driven by LUNA. Stock-based compensation expense included in research and development expenses was $1.9 million for the fourth quarter of 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **General and administrative expenses** were $11.7 million for the three months ended December 31, 2022, compared to $11.9 million for the same period in 2021. General and administrative expenses remained relatively flat. Stock-based compensation expense included in general and administrative expenses was $3.3 million for the fourth quarter of 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Net loss** was $32.7 million, or $0.33 per basic and diluted share, for the three months ended December 31, 2022, compared to $34.4 million, or $0.35 per basic and diluted share, for the same period in 2021.

------

**About Wet Age-Related Macular Degeneration** 

Wet AMD, also known as neovascular AMD or nAMD, is an advanced form of AMD affecting approximately 10% of patients living with AMD. Wet AMD is a leading cause of blindness in people over 65 years of age, with approximately 20 million individuals worldwide living with this condition. New cases of wet AMD are expected to grow significantly worldwide as populations age. AMD is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately 10% of those cases.

**About Ixo-Vec in Wet AMD**

Adverum is developing ixoberogene soroparvovec (Ixo-vec), its clinical-stage gene therapy product candidate, for the treatment of wet AMD. Ixo-vec utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. Unlike other ophthalmic gene therapies that require surgery to administer the gene therapy under the retina (sub-retinal approach), Ixo-vec is designed to be administered as a one-time IVT injection in the physician's office, deliver long-term efficacy, reduce the burden of frequent anti-vascular endothelial growth factor (VEGF) injections, optimize patient compliance and improve vision outcomes for patients with wet AMD. In recognition of the need for new treatment options for wet AMD, the U.S. Food and Drug Administration granted Fast Track designation for Ixo-vec for the treatment of wet AMD. Ixo-vec also received PRIME designation from the European Medicines Agency.

**About LUNA Trial of Ixo-vec in Wet AMD Updates**

The LUNA trial is a double-masked, randomized, Phase 2 trial being conducted at approximately 40 sites in the U.S. and Europe. LUNA will evaluate Ixo-vec in subjects with wet AMD who are 50 years or older and have demonstrated a response to anti-VEGF treatment. Up to 72 subjects will be randomized equally between the previously evaluated 2E11 Ixo-vec dose and a new, lower 6E10 dose. Four prophylactic steroid regimens will be studied with the aim of establishing a prophylactic corticosteroid regimen with minimal need for inflammation management post prophylaxis. Prophylactic regimens being evaluated include 22 weeks of a tapered regimen of topical difluprednate (Durezol<sup>®</sup>), a single administration of IVT dexamethasone (Ozurdex<sup>®</sup>), and a combination of either topical Durezol<sup>®</sup> or IVT Ozurdex<sup>®</sup> with up to 10 weeks of a tapered regimen of oral prednisone, with the aim of establishing a prophylactic regimen with minimal need for inflammation management post prophylaxis. All four prophylactic corticosteroid regimens in LUNA cover the period of peak immunogenicity observed in non-clinical studies and in the Phase 1 OPTIC study.

The LUNA trial primary endpoints are mean change in best corrected visual acuity (BCVA) from baseline to one year as well as the incidence and severity of adverse events. Key secondary endpoints in LUNA include the mean change in central subfield thickness (CST) from baseline to one year and assessing the effectiveness of prophylactic steroid regimens on minimizing inflammation. Additionally, LUNA will assess aflibercept protein levels starting at Week 14 and include an interim analysis at Week 26. Study participants will have the option to enroll in a long-term extension study.

------

**About Adverum Biotechnologies** 

Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians' offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit <u>www.adverum.com</u>.

**Forward-looking Statements**

Statements contained in this press release regarding events or results that may occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements regarding the potential benefits of Ixo-vec, effectiveness of the prophylactic corticosteroid regimens, the timing of LUNA enrollment, screening patients in Europe, the timing of preliminary data from the LUNA trial, as well as cash runway to fund operations into 2025. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including risks inherent to, without limitation: Adverum's novel technology, which makes it difficult to predict the timing of commencement and completion of clinical trials; regulatory uncertainties; enrollment uncertainties; the results of early clinical trials not always being predictive of future clinical trials and results; and the potential for future complications or side effects in connection with use of Ixo-vec. Additional risks and uncertainties facing Adverum are set forth under the caption "Risk Factors" and elsewhere in Adverum's Securities and Exchange Commission (SEC) filings and reports, including Adverum's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, and future filings and reports by Adverum, including Adverum's Annual Report on Form 10-K for the year ended December 31, 2022. All forward-looking statements contained in this press release speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

**Corporate, Investor and Media Inquiries** 

Anand Reddi

Vice President, Head of Corporate Strategy, External Affairs and Engagement

Adverum Biotechnologies, Inc.

T: 650-649-1358

E: <u>areddi@adverum.com</u>

------

![advm_bsa.jpg](advm_bsa.jpg)

------

![advm_isxfy22a.jpg](advm_isxfy22a.jpg)

<br>